Background: Rheumatoid arthritis (RA) is a complex inflammatory disease that has features of atherosclerosis and cognitive decline. Although the relationship between atherosclerosis and cognitive impairment has been studied and replicated, whether cognitive deficits in RA can be attributed to their atherosclerotic changes is not well understood. Objectives: This study investigated the cognitive function in patients with RA using the Korean version of the Consortium to Establish a Registry for Alzheimer's disease (CERAD-K) neuropsychological battery and evaluated whether cognitive function was affected by the carotid arterial atherosclerosis. Methods: We examined seventy RA patients and forty healthy controls. RA activity was assessed by disease activity score with 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and objective memory impairment was defined as a performance score of 1.5 standard deviations below the respective agespecific, education-specific, and sex-specific normative means for at least one of the four episodic memory tests in CERAD-K; the Word List Memory, Word List Recall, Word List Recognition, and Constructional Recall tests [1] . Carotid arteries were scanned for the presence of plaque and intima-media thickness (IMT). We assessed potential risk factors of cognitive impairment in RA patients using regression analyses. Results: Of the CERAD-K subtests, there were a significant difference between the RA patients and healthy controls in verbal fluency (12.97±3.73 vs 15.48±4.57, respectively; p=0.004) and Boston Naming Test (11.50±2.08 vs 12.30±1.77, respectively; p=0.035). Carotid ultrasound revealed significantly more plaques in the RA patients than in the healthy controls (39% vs 15%, respectively; p=0.017). RA patients with memory impairment have significantly higher score of DAS28-ESR (4.14±0.99 vs 2.60±0.88, respectively; p<0.001), age (65.71±7.71 vs 58.50±11.33, respectively; p=0.009), and mean cIMT (0.56±0.10 vs 0.50±0.08, respectively; p=0.027) compared to RA patients without memory impairment. In multivariable regression analysis, CERAD-K total score showed a significant negative correlation with age (β=-0.415, p<0.001) or DAS28-ESR (β=-4.685, p<0.001), but no correlation was found between CERAD-K total score and presence of plaque or cIMT (Table 1) .
Conclusions:
Our results indicate that disease activity of RA and aging contribute to cognitive impairment, but there was no association between cognitive function and clinical or subclinical carotid atherosclerotic changes in RA patients. Background: Patient global assessment (PGA) of disease activity is included in a large number of composite indices of disease activity and definitions of remission in Rheumatoid Arthritis (RA). However, the actual question is formulated in a variety of different ways according to the instrument considered. Objectives: To evaluate how 6 different formulations of PGA affect patient estimates and impact upon disease activity and remission rates as assessed by 4 Disease Activity Indices. Methods: Consecutive RA patients followed in a Rheumatology outpatient department were included in this cross-sectional study. Data collection comprised: 28 joint counts (tender and swollen), C-reactive protein (CRP) and 6 different PGA formulations. The chosen formulations were the ones stated in the: v1) Portuguese National Registry Reuma.pt, the locally used formulation; v2) ACR/EULAR provisional definition of remission (considered in this study as the "standard"); v3) CDAI and SDAI; v4) Disease Activity Score (DAS28) assessment of general health; v5) DAS28 assessment of disease activity (the currently used); v6) one, exploratory, developed by the investigators, including idiomatic cultural expressions. ACR/EULAR Boolean criteria, CDAI, SDAI, and DAS28-CRP (4v) were used to test how these 6 PGA formulations change the rates of remission. PGA differences were assessed by descriptive analyses (including patients with PGA ≤10 and ≤20mm) and Bland-Altman test.
Results: In total, 193 patients were included (82% female, mean (SD) age of 59 (13) years, mean disease duration of 12 (9) years and 31% under biologics). The average PGA ranged from 42.3 (25.3) to 48.1 (26.7)mm as measured in different formulations. The ACR/EULAR (v2) formulation yielded the largest proportion of patients scoring ≤10mm (16.1%), corresponding to a difference of up to 4.7% versus other PGAs. Similar results were found for the ≤20 cut-off (Table 1) . By using different PGA's formulations the rates of remission calculated with different indices can vary between 4.7% and 6.7% (Table 2) . Bland-Altman chart confirmed the low agreement between ACR/EULAR formulation and the other PGA formulations (p<.05), except for the DAS "general health" (p=.054). 1 Quality of life (Qol) in patients with RA may be substantially impacted by their inability to perform daily activities, a shift in family roles, more restricted employment opportunities, increased financial burden and social dependency and reduced recreational activities. Objectives: To investigate the Qol among RA patients and its association with demographic and socioeconomic details. Methods: This is a cross-sectional study conducted in a rheumatology outpatient clinic in Malaysia. Patients who fulfilled 2010 ACR/ EULAR classification criteria for RA were asked to answer WHOQOL-BREF questionnaire and specific questions on demographics and socio-economic details, during their attendance to rheumatology clinics. WHOQOL-BREF is a self-report quality of life questionnaire on individual's perception of quality of life and health, physical health, psychological, social relationships and environment domains. Data was analysed using SPSS 20. Student's t-test was used to analyse the mean difference between two groups and chi-square test was used to analyse between 2 categorical data. Pearson correlation was used to analyse correlation between two groups of continuous data. p<0.05 was considered significant. Results: The mean age of patients in this study was 53.10 (±14.3) years, with majority being females (80.4%) and married (70.6%). Half of the patients were Malays (49.0%). 51.0% rated overall quality of life as good and 41.2% rated overall health as satisfied. The mean transformed scores were 55.2 (±15.9) in physical health, 57.3 (±15.9) in psychological, 59.2 (±18.1) in social relationships and 58.2 (±15.2) in environment domains. There were significant differences in the transformed scores for Malay (65.5±15.9) and non-Malay (53.1±18.2) in the social relationship domain; t (49) =2.58, p=0.01, and for education at secondary level and above (65.9±14.9) and primary level (48.0±16.6), t(49)=-3.87, p<0.01. We found no significant association between race and education level; 17 (53.1%) Malays and 15 (46.9%) non-Malays had education level of secondary and higher, X 2 (1, N=51) =0.58, p=0.48. Patients with household income of less than RM 3, 000 had significantly lower scores compared to those with higher household income, in overall perception of quality of life (3.3±0.9 vs 4.0±0.6; t(49)=-2.8, p<0.01), overall perception of health (2.9±0.9 vs 3.6±0.7, t(49)=-2.97, p<0.01), physical health domain (51.2±16.2 vs 63.8±11.6, t(49)=-2.78, p=0.01) and psychological domain (53.3±16.3 vs 66.1±10.9, t(49)=-2.85, p=0.01). Conclusions: Patients with RA perceived their Qol to be moderate in all domains. Social relationship was perceived to be better in Malays and patients with higher educational level. Low income was significantly associated lower overall quality of life and health, physical and psychological health. Table  1 . 29 patients (%2.4) were diagnosed as ILD with regard to CT findings. Patients with ILD were older (64.5±6.7 vs 60.6±10.1, p=0.039) and more frequently positive for rheumatoid factor (RF) (25/27 (%92.6) vs 77/121 (%63.3), p=0.003) than patients without ILD. ILD was detected before beginning of biologics in 11 (37.9%) patients and during biologic treatment in 18 (62.1%) patients. Honeycombing was seen in 10 (34.5%) patients. First choice of biologic agent was RTX in 10 (34.5%) and TNFi in 19 (65.5%) patients. In ILD patients, mean follow-up duration was 51±31 months and first biologic was switched to another in 16 (55.2%) of patients. At the last follow-up visit 19 (65.5%) patients were on rituximab, 3 (10.3%) patients were on abatacept and 7 (24.1%) were on TNFi. Small airway disease was detected in 19 (9.3%) patients. History of smoking was present in only 4 (21.0%) of patients with small airway disease. 
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